To appraise the clinical and cost effectiveness of lifitegrast within its marketing authorisation for treating dry eye disease.
Following on from information provided to NICE by the company in April 2019, the appraisal of Lifitegrast for treating dry eye disease [ID1229] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1229
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 08 November 2022 | Discontinued. Following on from information provided to NICE by the company in April 2019, the appraisal of Lifitegrast for treating dry eye disease [ID1229] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 09 July 2020 | Note added to the project documents |
| 08 July 2019 | Note added to the project documents |
| 24 June 2019 | Suspended. Suspended |
| 20 July 2018 | In progress. Following a regulatory update from the company (Shire Pharmaceuticals) this appraisal has been rescheduled. The timelines have been revised and the appraisal is now expected to start in June 2019, with the deadline for submissions August 2019. The appraisal will follow the new technology appraisal process (April 2018). |
| 05 September 2017 (00:00) | Scoping workshop |
| 17 July 2017 - 14 August 2017 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual